<?xml version="1.0" encoding="UTF-8" ?> 
<rss version="2.0"> 
<channel> 
  <title>제약 보도자료 - 뉴스와이어</title>  
  <link>https://www.newswire.co.kr/?md=A01&amp;cat=1000&amp;cat1=1001</link>  
  <description>제약 보도자료 - 뉴스와이어 RSS 서비스</description>  
  <lastBuildDate>Tue, 13 Oct 2026 09:58:06 +0900</lastBuildDate>  
  <copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright>  
  <webMaster>gichan2@newswire.co.kr</webMaster>  
  <language>ko</language>  
 <image> 
  <title>Newswire</title>  
  <url>https://static.newswire.co.kr/images/logo/logo_rss.png</url>  
  <link>https://www.newswire.co.kr</link>  
  <description>Newswire - 보도자료 통신사 뉴스와이어</description>  
 </image> 
  <item> 
  <title><![CDATA[Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044437&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[LEXINGTON, Mass.--(Business Wire/Korea Newswire)--Agenus Inc.  (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botens...]]></description> 
  <pubDate>Mon, 12 Oct 2026 17:20:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[아르메니아, 이전에 치료를 받은 MSS 전이성 직장암 환자를 대상으로 아제너스의 BOT+BAL에 대한 최초 판매 허가 승인]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044436&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[렉싱턴, 매사추세츠--(Business Wire/뉴스와이어)--면역항암제 혁신의 선두주자인 아제너스(Agenus Inc.) (나스닥: AGEN)는 아르메니아 보건부가 보트비모(Botvymo®, 보텐실리맙 또는 BOT) 및 에밤플릭스(Evamplix®, 발스틸리맙 또는 BAL)에 대한 판매 허가를 승인했...]]></description> 
  <pubDate>Mon, 12 Oct 2026 17:20:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[동아제약, 이부프로펜 액상스틱 감기약 ‘판피린타임 이부프로펜’ 3종 출시]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044448&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/.jpg" width="80" border="0" /></a></td></tr></table>서울--(뉴스와이어)--동아제약(대표이사 사장 김민영)은 이부프로펜을 주성분으로 한 감기약 ‘판피린타임 이부프로펜’ 3종을 출시했다고 12일 밝혔다. 이번 신제품은 △판피린타임 이부프로펜 콜드 △판피린타임 이부프로펜 코프 △판피린타임 이부프로펜 노즈로 총 3종...]]></description> 
  <pubDate>Mon, 12 Oct 2026 15:33:05 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[영진약품, 프랑스 아테나와 라세카도트릴 산제 국내 도입 계약 체결]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044305&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[서울--(뉴스와이어)--영진약품(대표이사 이기수)은 프랑스 제약사 아테나(Athena)와 라세카도트릴(racecadotril) 산제의 국내 도입을 위한 라이선스 계약 및 제품 공급 계약을 체결했다. 이번 계약은 기존 라세카도트릴 캡슐제에 이어 산제까지 제품군을 확대하고, ...]]></description> 
  <pubDate>Thu, 08 Oct 2026 17:20:02 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044275&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[ZUG, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall ...]]></description> 
  <pubDate>Thu, 08 Oct 2026 14:34:17 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044264&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[MONTREAL--(Business Wire/Korea Newswire)--Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North America and establishing a broader framework ...]]></description> 
  <pubDate>Thu, 08 Oct 2026 14:15:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[메디스카-유로API, 의약품 조제 분야의 API 접근성 강화 위한 전략적 파트너십 체결]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044262&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[몬트리올--(Business Wire/뉴스와이어)--메디스카(Medisca)와 유로API(EUROAPI)이 의약품 조제용 API 접근성 확대에 초점을 맞춘 전략적 파트너십을 체결하여 북미 시장에서의 차별화된 접근성을 확보하고 국제적 성장 및 펩타이드 협력을 위한 보다 폭넓은 틀을 구...]]></description> 
  <pubDate>Thu, 08 Oct 2026 14:15:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044125&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[SAN DIEGO--(Business Wire/Korea Newswire)--Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation seque...]]></description> 
  <pubDate>Wed, 07 Oct 2026 11:20:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[인비보스크라이브®, 포괄적인 림포트랙® 플렉스 제품군으로 분자 클론성 검사 포트폴리오 확장]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044123&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[샌디에이고--(Business Wire/뉴스와이어)--정밀 진단 및 측정 가능한 잔존 질환(MRD) 검사의 글로벌 리더인 인비보스크라이브(Invivoscribe)가 면역글로불린 및 T세포 수용체 유전자 재배열을 식별하고 추적하기 위한 통합 차세대 염기서열분석(NGS) 솔루션인 완전한...]]></description> 
  <pubDate>Wed, 07 Oct 2026 11:20:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044068&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[ZUG, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30 years since Restylane was launched in Europe as the first hyaluronic acid (HA) injectable.[1] With HA closest to the s...]]></description> 
  <pubDate>Tue, 06 Oct 2026 16:10:27 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[지놈앤컴퍼니, 미국신장학회 참가… First-in-class 섬유화 치료제 GENC-116 최신 데이터 공개]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044052&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[성남--(뉴스와이어)--글로벌 신약 개발 전문기업 지놈앤컴퍼니(코스닥 314130, 대표이사 홍유석, 배지수, 박한수)는 오는 10월 22~25일 미국 덴버에서 개최되는 ‘미국신장학회 학술대회(ASN Kidney Week 2026, 이하 ASN 2026)’에 참가해 신규타깃 파이프라인인 섬유...]]></description> 
  <pubDate>Tue, 06 Oct 2026 14:56:54 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[GC녹십자, 국내 최초 자체 개발 아젤라산 여드름 치료제 ‘아젤라힐크림’ 출시]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1044015&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/.jpg" width="80" border="0" /></a></td></tr></table>용인--(뉴스와이어)--GC녹십자(대표 허은철)는 자체 개발 및 생산한 아젤라산 성분의 여드름 치료제 ‘아젤라힐크림’을 새롭게 출시했다고 6일 밝혔다. 이번에 출시한 ‘아젤라힐크림’은 GC녹십자가 자체 개발한 아젤라산 성분의 일반의약품이다. 지난 7월 국내 제약사...]]></description> 
  <pubDate>Tue, 06 Oct 2026 10:20:01 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[GE HealthCare to Acquire SOFIE Biosciences, Establishing a ‘Final Mile’ Footprint for PET Radiopharmaceutical Supply in the U.S.]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1043999&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/.jpg" width="80" border="0" /></a></td></tr></table>CHICAGO--(Business Wire/Korea Newswire)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of...]]></description> 
  <pubDate>Tue, 06 Oct 2026 09:33:53 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Curia, 무균 API 생산에 2800만달러 투자]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1043987&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/.jpg" width="80" border="0" /></a></td></tr></table>올버니, 뉴욕--(뉴스와이어)--글로벌 선도 위탁개발생산기관(CDMO) Curia Global, Inc.(이하 Curia)는 스페인 바야돌리드(Valladolid)에서 스테로이드 및 비스테로이드 제품을 위한 무균 원료의약품(API) 생산 역량을 확대하기 위한 전략적 투자를 단행한다고 밝혔다...]]></description> 
  <pubDate>Tue, 06 Oct 2026 09:04:27 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1043984&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[LEXINGTON, Mass.--(Business Wire/Korea Newswire)--Agenus Inc.  (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The stu...]]></description> 
  <pubDate>Mon, 05 Oct 2026 15:35:00 +0900</pubDate> 
  </item> 
</channel> 
</rss> 
